'Medical Patent News' Tag

• Researchers receive BioBank DNA samples to unveil psoriasis genetics

  September 3, 2010

  [Story ID: 3553] Millions of Americans struggling with psoriasis and psoriatic arthritis are one step closer to a cure with the release of the first National Psoriasis Victor Henschel BioBank DNA samples for use in research at the University of Michigan Health System; research that hopes to uncover the unknowns about the genetics of psoriasis [...]

  posted in Uncategorized by admin

• USFDA grants Sun Pharma subsidiary approval for generic Strattera capsules ANDA

  September 2, 2010

  [Story ID: 3547] Sun Pharmaceutical Industries Ltd. announced that USFDA has granted its subsidiary an approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Strattera ®, atomoxetine hydrochloride capsules.

  posted in Uncategorized by admin

• Tooth brush in a teenagers stomach

  August 31, 2010

  [Story ID: 3539] A 15-year-old girl in New Zealand came to the emergency department at an Auckland hospital after accidentally swallowing her 19-centimetre toothbrush. The case study was published in the New Zealand Medical Journal.

  posted in Uncategorized by admin

• AOD Software named to 2010 Inc. 5000 list of fastest-growing private companies

  August 31, 2010

  [Story ID: 3529] Inc. magazine ranked AOD Software on its annual Inc. 5000, an exclusive ranking of the nation’s fastest-growing private companies. The list represents the most comprehensive look at the most important segment of the economy ‘

  posted in Uncategorized by admin

• GWAS finds new genetic target for Parkinsons disease drug development

  August 30, 2010

  [Story ID: 3520] A hunt throughout the human genome for variants associated with common, late-onset Parkinson’s disease has revealed a new genetic link that implicates the immune system and offers new targets for drug development.

  posted in Uncategorized by admin

• HHS awards University of Texas at Austin $2.7M for new Health Information Technology program

  August 27, 2010

  [Story ID: 3507] The University of Texas at Austin’s new Health Information Technology program has received $2.7 million as a part of the Professional University Resources and Education for Health Information Technology (PURE HIT) consortium project supported by a grant from the U.S. Department of Health and Human Services Office of the National Coordinator (ONC) [...]

  posted in Uncategorized by admin

• SU2C, Virgin America enter partnership to raise awareness and funds for cancer research

  August 27, 2010

  [Story ID: 3498] Stand Up To Cancer (SU2C) and Virgin America, the California-based airline that is reinventing travel, today announce a unique partnership to raise awareness and funds for cancer research. As SU2C’s Official Domestic Airline partner, Virgin America (with Virgin Unite) has pledged to support SU2C’s mission through a multi-year in-kind travel partnership, Company [...]

  posted in Uncategorized by admin

• Europes pharma sector faces increasing challenges

  August 26, 2010

  [Story ID: 3486] The Wall Street Journal: “After a healthy second quarter, Europe’s pharmaceutical sector may find itself in trouble in the months ahead as companies face patent expiries, tougher regulation and burdensome health care reforms.

  posted in Uncategorized by admin

• NTIs RxNT eHr V 7.0 earns additional certification in CCHITs Preliminary ARRA IFR Stage 1 program

  August 25, 2010

  [Story ID: 3479] Networking Technology, Inc., the leader in electronic health solutions, today announced that their electronic health record modular technology, RxNT eHr V 7.0 earned additional certification in CCHIT’s Preliminary ARRA IFR Stage 1 program.

  posted in Uncategorized by admin

• Pfizers Prevenar pneumococcal 13-valent conjugate vaccine receives WHO prequalification

  August 24, 2010

  [Story ID: 3471] The World Health Organization (WHO) has granted prequalification to Prevenar 13 (Pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed])for active immunization of infants and children from 6 weeks through five years of age against invasive disease, pneumonia and otitis media caused by the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, [...]

  posted in Uncategorized by admin